Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up
Purpose. The purpose of the study was to assess the efficacy of intravitreal dexamethasone implant (IDI: Ozurdex®) injection in eyes with macular edema due to retinal vein occlusion. Material and Method. A retrospective, nonrandomized study was conducted in patients with macular edema (ME) due to re...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2020/6830148 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560849119608832 |
|---|---|
| author | Cristina Nicula Dorin Nicula Anca Rednik Adriana Bulboaca Ovidiu Crișan |
| author_facet | Cristina Nicula Dorin Nicula Anca Rednik Adriana Bulboaca Ovidiu Crișan |
| author_sort | Cristina Nicula |
| collection | DOAJ |
| description | Purpose. The purpose of the study was to assess the efficacy of intravitreal dexamethasone implant (IDI: Ozurdex®) injection in eyes with macular edema due to retinal vein occlusion. Material and Method. A retrospective, nonrandomized study was conducted in patients with macular edema (ME) due to retinal vein occlusion (RVO) who undertook intravitreal Ozurdex® as first-line treatment. We performed a complete ocular exam including macular OCT. Results. The mean BCVA (logMar) improved from 0.420.42 ± 0.23 logMar at baseline to 0.21 ± 0.23 logMar at 48 weeks in the BRVO group and from 0.72 ± 0.16 logMar at baseline to 0.31 ± 0.23 logMar at 48 weeks in the CRVO group. In both groups, CFT values decreased significantly compared to baseline (p<0.0001 at each timepoint). Reinjection for recurrent macular edema after 18 weeks was indicated in five eyes (41.67%) in the BRVO group and in six eyes (25%) in the CRVO group. Cataract developed in two eyes (16.67%) in the BRVO group and in one eye (4.17%) in the CRVO group. The IOP was higher than 25 mmHg in two cases in the BRVO group (16.66%) and in three cases (8.33%) in the CRVO group. Conclusion. Ozurdex® injected intravitreally significantly improved the mean CFT and BCVA in eyes with macular edema due to retinal vein occlusion. |
| format | Article |
| id | doaj-art-02a77442d17f4d8f97c702d4b9db70dd |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-02a77442d17f4d8f97c702d4b9db70dd2025-02-03T01:26:25ZengWileyJournal of Ophthalmology2090-004X2090-00582020-01-01202010.1155/2020/68301486830148Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-UpCristina Nicula0Dorin Nicula1Anca Rednik2Adriana Bulboaca3Ovidiu Crișan4University of Medicine and Pharmacy “Iuliu Hațieganu”, Faculty of Medicine, Department of Ophthalmology, Cluj-Napoca, RomaniaOculens Clinic, Cluj-Napoca, RomaniaEmergency County Eye Hospital, Cluj-Napoca, RomaniaUniversity of Medicine and Pharmacy “Iuliu Hațieganu”, Faculty of Medicine, Department of Physiopathology, Cluj-Napoca, RomaniaUniversity of Medicine and Pharmacy “Iuliu Hațieganu”, Faculty of Pharmacy, Department of Organic Chemistry, Cluj-Napoca, RomaniaPurpose. The purpose of the study was to assess the efficacy of intravitreal dexamethasone implant (IDI: Ozurdex®) injection in eyes with macular edema due to retinal vein occlusion. Material and Method. A retrospective, nonrandomized study was conducted in patients with macular edema (ME) due to retinal vein occlusion (RVO) who undertook intravitreal Ozurdex® as first-line treatment. We performed a complete ocular exam including macular OCT. Results. The mean BCVA (logMar) improved from 0.420.42 ± 0.23 logMar at baseline to 0.21 ± 0.23 logMar at 48 weeks in the BRVO group and from 0.72 ± 0.16 logMar at baseline to 0.31 ± 0.23 logMar at 48 weeks in the CRVO group. In both groups, CFT values decreased significantly compared to baseline (p<0.0001 at each timepoint). Reinjection for recurrent macular edema after 18 weeks was indicated in five eyes (41.67%) in the BRVO group and in six eyes (25%) in the CRVO group. Cataract developed in two eyes (16.67%) in the BRVO group and in one eye (4.17%) in the CRVO group. The IOP was higher than 25 mmHg in two cases in the BRVO group (16.66%) and in three cases (8.33%) in the CRVO group. Conclusion. Ozurdex® injected intravitreally significantly improved the mean CFT and BCVA in eyes with macular edema due to retinal vein occlusion.http://dx.doi.org/10.1155/2020/6830148 |
| spellingShingle | Cristina Nicula Dorin Nicula Anca Rednik Adriana Bulboaca Ovidiu Crișan Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up Journal of Ophthalmology |
| title | Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up |
| title_full | Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up |
| title_fullStr | Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up |
| title_full_unstemmed | Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up |
| title_short | Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up |
| title_sort | morphological and functional outcomes after intravitreal dexamethasone injection for macular edema in patients with central vein occlusion at 48 week follow up |
| url | http://dx.doi.org/10.1155/2020/6830148 |
| work_keys_str_mv | AT cristinanicula morphologicalandfunctionaloutcomesafterintravitrealdexamethasoneinjectionformacularedemainpatientswithcentralveinocclusionat48weekfollowup AT dorinnicula morphologicalandfunctionaloutcomesafterintravitrealdexamethasoneinjectionformacularedemainpatientswithcentralveinocclusionat48weekfollowup AT ancarednik morphologicalandfunctionaloutcomesafterintravitrealdexamethasoneinjectionformacularedemainpatientswithcentralveinocclusionat48weekfollowup AT adrianabulboaca morphologicalandfunctionaloutcomesafterintravitrealdexamethasoneinjectionformacularedemainpatientswithcentralveinocclusionat48weekfollowup AT ovidiucrisan morphologicalandfunctionaloutcomesafterintravitrealdexamethasoneinjectionformacularedemainpatientswithcentralveinocclusionat48weekfollowup |